Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Carsten Bokemeyer; I Bondarenko; J T Hartmann; F de Braud; Gunter Schuch; A Zubel; I Celik; M Schlichting; P Koralewski

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Standard

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. / Bokemeyer, Carsten; Bondarenko, I; Hartmann, J T; de Braud, F; Schuch, Gunter; Zubel, A; Celik, I; Schlichting, M; Koralewski, P.

In: ANN ONCOL, Vol. 22, No. 7, 7, 2011, p. 1535-1546.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bokemeyer, C, Bondarenko, I, Hartmann, JT, de Braud, F, Schuch, G, Zubel, A, Celik, I, Schlichting, M & Koralewski, P 2011, 'Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.', ANN ONCOL, vol. 22, no. 7, 7, pp. 1535-1546. <http://www.ncbi.nlm.nih.gov/pubmed/21228335?dopt=Citation>

APA

Bokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011). Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. ANN ONCOL, 22(7), 1535-1546. [7]. http://www.ncbi.nlm.nih.gov/pubmed/21228335?dopt=Citation

Vancouver

Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. ANN ONCOL. 2011;22(7):1535-1546. 7.

Bibtex

@article{341a07c80ef14cfebc43066d3c87b346,

title = "Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.",

abstract = "The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC).",

keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Young Adult, Treatment Outcome, Survival Rate, Follow-Up Studies, Polymerase Chain Reaction, DNA, Neoplasm/genetics, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Leucovorin/administration & dosage, Antibodies, Monoclonal/administration & dosage, Proto-Oncogene Proteins/*genetics, Tumor Markers, Biological/*genetics, ras Proteins/*genetics, Mutation/*genetics, Colorectal Neoplasms/*drug therapy/genetics/pathology, Fluorouracil/administration & dosage, Liver Neoplasms/*drug therapy/genetics/secondary, Organoplatinum Compounds/administration & dosage, Proto-Oncogene Proteins B-raf/genetics, Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Young Adult, Treatment Outcome, Survival Rate, Follow-Up Studies, Polymerase Chain Reaction, DNA, Neoplasm/genetics, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Leucovorin/administration & dosage, Antibodies, Monoclonal/administration & dosage, Proto-Oncogene Proteins/*genetics, Tumor Markers, Biological/*genetics, ras Proteins/*genetics, Mutation/*genetics, Colorectal Neoplasms/*drug therapy/genetics/pathology, Fluorouracil/administration & dosage, Liver Neoplasms/*drug therapy/genetics/secondary, Organoplatinum Compounds/administration & dosage, Proto-Oncogene Proteins B-raf/genetics",

author = "Carsten Bokemeyer and I Bondarenko and Hartmann, {J T} and {de Braud}, F and Gunter Schuch and A Zubel and I Celik and M Schlichting and P Koralewski",

year = "2011",

language = "English",

volume = "22",

pages = "1535--1546",

journal = "ANN ONCOL",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "7",

}

RIS

TY - JOUR

T1 - Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

AU - Bokemeyer, Carsten

AU - Bondarenko, I

AU - Hartmann, J T

AU - de Braud, F

AU - Schuch, Gunter

AU - Zubel, A

AU - Celik, I

AU - Schlichting, M

AU - Koralewski, P

PY - 2011

Y1 - 2011

N2 - The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC).

AB - The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC).

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Young Adult

KW - Treatment Outcome

KW - Survival Rate

KW - Follow-Up Studies

KW - Polymerase Chain Reaction

KW - DNA, Neoplasm/genetics

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Leucovorin/administration & dosage

KW - Antibodies, Monoclonal/administration & dosage

KW - Proto-Oncogene Proteins/genetics

KW - Tumor Markers, Biological/genetics

KW - ras Proteins/genetics

KW - Mutation/genetics

KW - Colorectal Neoplasms/drug therapy/genetics/pathology

KW - Fluorouracil/administration & dosage

KW - Liver Neoplasms/drug therapy/genetics/secondary

KW - Organoplatinum Compounds/administration & dosage

KW - Proto-Oncogene Proteins B-raf/genetics